Clinical Trial

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated August 18, 2023 (before its estimated August 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
A clinical study was conducted to evaluate the efficacy and safety of the RCMOP regimen sequential therapy as a first-line treatment for patients with intermediate-to-high risk diffuse large B-cell lymphoma who had incomplete remission.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05990985
Lead Sponsor The First Hospital of Jilin University
Collaborators: CSPC Ouyi Pharmaceutical Co., Ltd.
Conditions Diffuse Large B-cell Lymphoma
Enrollment 20 participants
Start Date 2023-09-01
Primary Completion 2024-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2023-08-18